The abstract is read at the publisher; the summary is JClub's.
Adding eltrombopag to cyclosporine significantly increases week-24 overall response rate in moderate aplastic anemia, reaching 71.4% versus 42.5% with placebo.
- Why it matters: Moderate aplastic anemia lacks a consensus first-line regimen, and patients need better hematologic recovery than cyclosporine alone.
- What they did: In a multicenter, randomized, placebo-controlled, double-blind phase 3 trial, eltrombopag plus CSA (n = 41) was compared with placebo plus CSA (n = 44) in first-line treatment.
- The result: Among evaluable patients at week 24 (n = 75), ORR was higher with eltrombopag (P = .011), and placebo non-CR patients switched to eltrombopag achieved 73.5% ORR by week 48 (P = .009).
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.